>
产品中心 >
In Vivo Tn5 Transposon Mutagenesis >
Lucigen/TypeOne™ Restriction Inhibitor/TY0261H/100 µg
暂无问答
>
Lucigen/TypeOne™ Restriction Inhibitor/TY0261H/100 µgSize: | 100 µg |
Applications
DNA transformation can be difficult to achieve in many bacterial strains due to the presence of one or more restriction and modification (R-M) systems that cleave unmodified DNA that is recognized as "foreign." TypeOne™ Restriction Inhibitor* provides a powerful method for increasing transformation efficiencies in bacterial strains with type I R-M systems. Developed as a unique preparation of a phage protein called ocr,1 TypeOne Inhibitor is reADIly electroporated into cells along with transforming DNA. In vivo, the protein acts as a molecular decoy that blocks the DNA-binding site of type I R-M enzymes and inhibits DNA cleavage.
Benefits
Table 1. Effect of TypeOne™ Restriction Inhibitor on transformation efficiencies.
Strain (Type I R-M system) | TypeOne™ Inhibitor | Type of DNA or Transposome™ | Recombinants per µg DNA |
S. typhimurium LT2 (StyL TIII) | pUC19 (100 pg) | 3.0 × 106 | |
S. typhimurium LT2 (StyL TIII) | X | pUC19 (100 pg) | 3.0 × 108 |
E. coli MG1655 (EcoK1) | 48 kb fosmid (50 ng) | 3.0 × 103 | |
E. coli MG1655 (EcoK1) | X | 48 kb fosmid (50 ng) | 1.4 × 106 |
S. typhimurium LT2 (StyL TIII) | EZ-Tn5™ <R6Kγori/KAN-2>Tnp Transposome™ (1 µl) | 1.3 × 104 | |
S. typhimurium LT2 (StyL TIII) | X | EZ-Tn5™ <R6Kγori/KAN-2>Tnp Transposome™ (1 µl) | 1.0 × 106 |
References
*Covered by issued and/or pending patents, exclusively licensed or assigned to Epicentre® (an Illumina® Company).
美国Lucigen公司,自1998年成立至今,一直致力于生命科学领域相关科研产品的研究与开发,在分子生物学领域处于领导性地位。Lucigen公司主要开发各类用于基因克隆的试剂盒及相关产品,包括:CloneSmart®平端克隆试剂盒、BigEasy®线性克隆系统、pEZSeq™平端克隆试剂盒、ClonePlex™ AK文库构建试剂盒、DNA Terminator ®末端修复试剂盒、EconoTaq® DNA聚合酶及E.cloni感受态细胞等。Lucigen公司凭借其独到的产品技术,过硬的产品质量,良好的产品服务赢得了全球广大用户的信赖。